Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Inks Marketing Deal with LI Path for Prostate Cancer Test

NEW YORK (GenomeWeb News) – MDxHealth today said that it has signed a co-marketing agreement with Long Island Pathology to promote MDxHealth's ConfirmMDx for Prostate Cancer test.

LI Path is an independent anatomic and clinical pathology lab serving the New York City metropolitan area, and MDxHealth expects the deal to expand its access to urologists in that market. Financial and other terms of the agreement were not disclosed.

"The ConfirmMDx for Prostate Cancer test provides actionable information to help urologists better stratify patients at risk for undetected prostate cancer and guide the decision for repeat biopsy," LI Path CEO Ken Cerney said in a statement. "The addition ConfirmMDx to our portfolio of tests enhances our ability to serve our clients."

MDxHealth's ConfirmMDx for Prostate Cancer is an epigenetic assay intended to help urologists distinguish patients who have a true negative biopsy from those at risk for occult cancer.